Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08VXF
|
|||
| Former ID |
DNC012231
|
|||
| Drug Name |
Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine
|
|||
| Synonyms |
CHEMBL95332; 109292-93-5; 9H-Purin-6-amine, N-cyclohexyl-9-methyl-; N6-Cyclohexyl-9-methyladenine; Cyclohexyl-(9-methyl-9H-purin-6-yl)-amine; ACMC-20mc61; SCHEMBL14564552; CTK0D5868; DTXSID10576963; BDBM50009683; 6-Cyclohexylamino-9-methyl-9H-purine; AKOS030562210
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C12H17N5
|
|||
| Canonical SMILES |
CN1C=NC2=C(N=CN=C21)NC3CCCCC3
|
|||
| InChI |
1S/C12H17N5/c1-17-8-15-10-11(13-7-14-12(10)17)16-9-5-3-2-4-6-9/h7-9H,2-6H2,1H3,(H,13,14,16)
|
|||
| InChIKey |
YWCWGJZQICOVCA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 109292-93-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| cAMP signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Adenosine P1 receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Nucleotide GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | N6,9-disubstituted adenines: potent, selective antagonists at the A1 adenosine receptor. J Med Chem. 1991 Sep;34(9):2877-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.